

Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma

Wouter J. Plattel,^{1,2} Anke van den Berg,² Lydia Visser², Anne-Marijn van der Graaf,^{1,2} Jan Pruim,³ Hans Vos,¹ Bouke Hepkema,⁴ Arjan Diepstra,² and Gustaaf W. van Imhoff¹

¹Department of Hematology; ²Department of Pathology and Medical Biology; ³Department of Nuclear Medicine and Molecular Imaging; and ⁴Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, the Netherlands

Citation: Plattel WJ, van den Berg A, Visser L, van der Graaf A-M, Pruim J, Vos H, Hepkema B, Diepstra A, and van Imhoff GW. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. *Haematologica* 2012;97(3):410-415. doi:10.3324/haematol.2011.053199

Online Supplementary Table S1. Plasma TARC dynamics and response in early stage cHL patients.

UPN	Baseline (n=39)	Plasma TARC level (pg/mL)		After treatment (n=39)	Response evaluation		First-line treatment
		After 1 cycle (n=34)	Mid-treatment (n=39) (after 2 ABVD)		Mid-treatment	End-treatment	
1*	96839	671	200	187	CR	CR	4x ABVD + IN-RT
2*	93413	85	118	92	CR	CR	4x ABVD + IN-RT
3	86334	256	219	127	CR	CR	4x ABVD + IN-RT
4	79313	229	482	564	CR	CR	4x ABVD
5	70283	590	933	819	CR	CR	6x ABVD
6	65787	140	85	104	CR	CR	6x ABVD
7*	61624	131	119	150	CR	CR	6x ABVD
8*	43050	205	174	167	CR	CR	4x ABVD + IN-RT
9*	31953	156	178	88	CR	CR	4x ABVD + IN-RT
10	28748	316	594	125	CR	CR	4x ABVD
11	23400	314	281	245	CR	CR	3x ABVD + IN-RT
12*	22436	616	119	220	CR	CR	4x ABVD
13	17540	86	53	79	CR	CR	3x ABVD + IN-RT
14	13350	206	346	101	CR	CR	3x ABVD + IN-RT
15	12614	178	114	61	CR	CR	4x ABVD + IN-RT
16*	12388	497	314	592	CR	CR	4x ABVD + IN-RT
17	12024	393	393	293	CR	CR	4x ABVD + IN-RT
18*	9428	196	173	134	CR	CR	6x ABVD
19*	8967	191	160	22	CR	CR	4x ABVD + IN-RT
20*	8248	169	352	216	CR	CR	6x ABVD
21	8103	227	193	271	CR	CR	3x ABVD + IN-RT
22	7066	no sample	100	71	CR	CR	3x ABVD + IN-RT
23	6760	135	69	382	CR	CR	4x ABVD + IN-RT
24	5652	444	271	91	CR	CR	4x ABVD + IN-RT
25	5118	139	225	292	CR	CR	4x ABVD + IN-RT
26	4174	153	25	138	CR	CR	4x ABVD + IN-RT
27	834^	no sample	292	409	CR	CR	4x ABVD + IN-RT
28	800^	no sample	120	194	CR	CR	4x ABVD + IN-RT
29	250^	285	122	54	CR	CR	3x ABVD + IN-RT
30	127^	no sample	256	107	CR	CR	3x ABVD + IN-RT
31	69^	95	70	164	CR	CR	6x ABVD
32*	135486	297	201	160	PR	CR	6x ABVD
33	48721	326	255	78	PR	CR	4x ABVD + IN-RT
34	27277	no sample	714	421	PR	CR	4x ABVD + IN-RT
35	19313	334	103	212	PR	CR	2x ABVD + 2x eBEACOPP + IN-RT
36*	5977	539	292	112	PR	CR	4x ABVD + IN-RT
37	1193	291	246	212	PR	CR	3x ABVD + IN-RT
38*	46298	220	64	83	PR	PR	2x ABVD + 2x eBEACOPP + IN-RT
39*	43048	12532	10873	9754	PR	PD	6x ABVD

*Patient with bulky disease; ^TARC expression by the HRS cells was confirmed by positive TARC staining in tissue samples; UPN: unique patient number; TARC: thymus and activation-regulated chemokine; CR: complete response; PR: partial response; PD: progressive disease.

Online Supplementary Table S2. Plasma TARC dynamics and response in advanced stage cHL patients.

UPN	Baseline (n=21)	Plasma TARC level (pg/mL)			Response evaluation		First-line treatment
		After 1 cycle (n=17)	Mid-treatment (n=19) (after 4 ABVD / (e)BEACOPP)	After treatment (n=21)	Mid-treatment	End-treatment	
40	197,160	254	294	261	CR	CR	8x ABVD
41	152,487	230	153	116	CR	CR	8x ABVD
42*	108,915	134	324	202	CR	CR	6x ABVD
43*	106,003	369	237	215	CR	CR	8x ABVD
44*	81,088	119	129	390	CR	CR	8x ABVD
45*	69,719	179	203	329	CR	CR	8x ABVD
46	64,422	438	465	456	CR	CR	6xABVD
47	47,783	487	246	297	CR	CR	4x eBEACOPP, 4x BEACOPP
48	47,739	233	285	296	CR	CR	6x ABVD
49*	45,183	373	73	725	CR	CR	6x ABVD
50	44,543	217	157	454	CR	CR	6x ABVD
51	32,194	153	105	110	CR	CR	6x ABVD
52	24,225	no sample	no sample	90	CR	CR	8x ABVD
53	11,124	82	72	144	CR	CR	4x eBEACOPP, 4x BEACOPP
54	10,465	no sample	78	311	CR	CR	8x ABVD
55	6,111	25	24	28	CR	CR	6x ABVD
56	4,221	no sample	no sample	88	CR	CR	5x BEACOPP
57	269,048	no sample	2302	217	PR	CR	4x eBEACOPP, 4x BEACOPP
58*	158,410	583	206	273	PR	PR	4x eBEACOPP, 4x BEACOPP
59*	236,288	99276	61365	136636	PR	PD	4x eBEACOPP, 4x BEACOPP
60*	182,908	2117	16965	19324	PR	PD	6x ABVD

*Patient with bulky disease; UPN: unique patient number; TARC: thymus and activation-regulated chemokine; CR: complete response; PR: partial response; PD: progressive disease.

Online Supplementary Table S3. Plasma TARC dynamics and response in relapsed cHL patients.

UPN	Plasma TARC level (pg/mL)		Response evaluation End-treatment	Salvage treatment
	At relapse (n=12)	After salvage treatment (n=12)		
61	91,863	122	CR	DHAP-VIM-DHAP +ASCT
62*	80,432	562	CR	DHAP-VIM-DHAP +ASCT
63	59,785	26	CR	DHAP-VIM-DHAP +ASCT
64	31,705	368	CR	DHAP-VIM-DHAP +ASCT
65	19,149	577	CR	DHAP-VIM-DHAP +ASCT
66	4,731	465	CR	DHAP-VIM-DHAP +ASCT
67	2,524	30	CR	DHAP-VIM-DHAP +ASCT
68	1,008	78	CR	DHAP-VIM-DHAP +ASCT
69	11,179	4,792	SD	DHAP, VIM, Mini-BEAM (2x) +ASCT
70	67,629	21,804	PD	DHAP-VIM-DHAP +ASCT
71	29,085	1,689	PD	DHAP, VIM, Mini-BEAM (2x) +ASCT
72	14,637	19,371	PD	DHAP, VIM, Mini-BEAM (2x) +ASCT

*Patient with bulky disease; UPN: unique patient number; TARC: thymus and activation-regulated chemokine; CR: complete response; SD: stable disease; PD: progressive disease.